TIME Trial Summary: Morning vs. Evening dose of Antihypertensives

time trial hypertension

2022 TIME TRIAL Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK prospective, open-label, blinded-endpoint, randomized controlled trial IM Objective: To compare the major cardiovascular outcomes of evening dosing of antihypertensive medication versus morning dosing in patients with hypertension treated with their usual antihypertensive medications 21104 patients Inclusion criteria: Patients ≥18 years, UK residents with hypertension, and taking ≥1 antihypertensive medication daily 3.4 VS ههتة Evening dosing (n=10,503) Morning dosing (n=10,601) PRIMARY OUTCOME Cardiovascular endpoint of vascular death or hospitalization for non-fatal MI or non-fatal stroke % HR 0.65; 95% CI, 0.38 to 1.09; P = 0.09 SECONDARY OUTCOMES 3.7 4.2 All-cause death % 4.1 HR 1.04; 95% CI, 0.91 to 1.18; P = 0.59 Hospitalization or death from congestive 0.7 heart failure % 0.9 HR 0.79; 95% CI, 0.59 to 1.07; P=0.12 Conclusion: Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Prof IS Mackenzie et al. Lancet 2022;400(10361):1417-1425

Comments are closed.